AADPA Board - July 2019

Our Board Of Directors

Comprising professionals in research, medicine and psychiatry, AADPA’s Board of Directors are bound by their shared commitment to providing evidence-based diagnosis, treatment and management of ADHD and are responsible for setting policy and overseeing the organization’s general well being.

Mark Bellgrove - AAPDA Board Member

Prof. Mark Bellgrove

AADPA President (29 July 2017 - Present)

Professor Bellgrove has studied the neurobiology of ADHD for over 15 years and is internationally known for his work on the genetics, neuropsychology and pharmacology of ADHD. His research achievements have been recognized with awards from NARSAD (USA), the Academy of Social Sciences in Australia and Biological Psychiatry Australia.

Mark is a strong advocate for evidenced-based diagnosis, treatment and management of ADHD and has a strong vision for the development of unified national diagnosis, prescribing and treatment practices and AADPA’s role in influencing policy to ensure a “better deal” for the many individuals affected by ADHD within Australia.

Disclosure

Prof. Bellgrove has in the past received a research grant from Eli Lily. He has received grants related to ADHD from the Science Foundation Ireland, the Irish Health Research Board, the National Health and Medical Research Council (NHMRC) Australia, the Murdoch Children’s Research Institute (Australia), National Alliance on Schizophrenia and Allied Disciplines (NARSAD) – US, and the Australian Research Council. He has received an educational grant from Shire. He has given educational talks at meetings sponsored by Janssen-Cilag, Eli Lilly and Shire. Prof. Bellgrove is a founding member and inaugural President of the Australian ADHD Professionals Association.

David Coghill - AADPA Board Member

Prof. David Coghill

Vice-President (29 July 2017 - Present)

Professor Coghill is committed to the development and implementation of evidence-based pathways for ADHD and has been involved in the development of several National and International Clinical guidelines for ADHD.

David’s research interests include neuroscience, neuropsychology, Neuropsychopharmacology, health services research, implementation science, clinical trials, pharmacovigilance and quality of life. He is the chair of EUNETHYDIS International conferences, a charity that supports education and research in ADHD and related disorders and is a longstanding member of the executive committee of the European Network for Hyperkinetic Disorders (EUNETHYDIS).

Disclosure

Prof. Coghill has received research support from Shire and Vifor Pharma. He has also received research grants related to ADHD from the EU, the National Institute for Health Research (NIHR) UK, National Health and Medical Research Council (NHMRC) Australia, the Murdoch Children’s Research Institute (Australia), Department of Health (UK). He has received honoraria for advisory boards/speaking from Shire, Eli Lilly, Janssen-Cilag, Medice, Novartis. He receives royalties from Oxford University Press. Prof. Coghill is a founding member and inaugural Vice-President of the Australian ADHD Professionals Association Ltd.

Roger Paterson - AADPA Board Member 2019 (1)

Dr Roger Paterson

Director (29 July 2017 - Present)

Dr Roger Paterson, MB BS, FRCPsych, FRANZCP, Cert. Child & Adol. Psych, has been active in the field of child, adolescent and adult ADHD for many years. In the public sector from 1989 to 1996 in child psychiatry, and in full-time general child and adult private practice thereafter, with the last few years being mostly an ADHD practice across the lifespan.

Disclosure

Recipient of Speaker’s fee received from Janssen, Eli Lilly, Novartis, Shire and Servier. Advisory Board paid member: Eli Lilly and Shire. Conference sponsorship: Astra-Zeneca, Janssen-Cilag, Lilly, Novartis, Pfizer, Shire and Solvay.

Christel Middeldorp - AADPA Board

Prof. Christel Middeldorp

Director (28 July 2018 - Present)

Professor Middeldorp’s research focuses on the role of genetic and other familial factors in the development and persistence of common psychiatric symptoms in childhood, including ADHD. She also investigates the role of parental mental health problems, on the outcome of psychiatric symptoms in a clinical cohort and will perform a trial to study whether addressing parental mental health also improves the outcome for the children.

Christel is committed to facilitating patient advocacy, increasing stakeholder representation and establishing an essential large network to investigate ADHD on the large scale that is necessary to identify biomarkers.  She also aims to translate the knowledge from the fundamental and clinical research via her contribution to the design of clinical guidelines.

Emma Sciberras - AADPA Board

Dr Emma Sciberras

Director (28 July 2018 - Present)

Dr Sciberras has worked in the area of ADHD for 13 years and has been recognised by the Australian Institute for Policy and Science for her achievements. She holds a National Health & Medical Research Council Career Development Fellowship focused on the development of evidence-based behavioural interventions to improve outcomes for young people with ADHD.

Emma is committed to reducing the stigma associated with ADHD and disseminating evidence-based information about the disorder to the general community. Her strong track record in ADHD research (>80 publications, ~$7M in research funding) will be invaluable in advocating for funding for the organisation and supporting AADPA’s activities more broadly.

Disclosure

Dr Sciberras has received grants related to ADHD from the National Health and Medical Research Council (NHMRC) Australia, the Murdoch Children’s Research Institute (Australia) and Deakin University.

Associate professor Tim Silk - AADPA Board Member

Assoc Prof. Tim Silk

Director (27 July 2019 - Present)

Associate Professor Tim Silk is a cognitive neuroscientist specializing in paediatric neurodevelopmental imaging in order to understand the brain-behaviour interface; when and where that goes awry. Specifically, he is focused on identifying neuroimaging markers that can be used to distinguish children with neurodevelopmental disorders, monitor progression, and predict outcome or treatment response.

Tim heads the Brain and Cognitive Development Lab, and currently leads The Neuroimaging of the Children’s Attention Project (NICAP) collecting longitudinal multimodal neuroimaging data in order to understand how brain structure and function change across late childhood to early adolescence for children with and without ADHD, and how those changes reflect ADHD symptom severity and functional outcomes.

Disclosure

Dr Silk has received research grants relating to ADHD from the National Health and Medical Research Council (NHMRC) of Australia, The Waterloo Foundation, and the Murdoch Children’s Research Institute (Australia).

Dr Alicia Montgomery - AADPA Board Member

Dr Alicia Montgomery

Director (March 2020 - Present)

Dr Alicia Montgomery is a specialist in developmental and behavioural Paediatrics with an interest in transdiagnostic neurodevelopmental clinical practice and research. Dr Montgomery is currently leading an interdisciplinary project for the Sydney Local Health District on new models of care for ADHD, and is also currently running pharmacological clinical trials in Autism Spectrum Disorder and Tourette Syndrome for the School of Psychiatry at the University of New South Wales.

Alicia is a member of the Neurodevelopmental and Behavioural Paediatric Society of Australasia, and represents the NBPSA on the Royal Australian College of Physician’s Committee for Community Child Health.